



REPORTED SALES vs. PRIOR PERIOD (\$MM)

**CONSUMER SEGMENT <sup>(2)</sup>**

	FOURTH QUARTER					TWELVE MONTHS				
	2018	2017	% Change			2018	2017	% Change		
			Reported	Operational <sup>(1)</sup>	Currency			Reported	Operational <sup>(1)</sup>	Currency
<b>BABY CARE</b>										
US	\$ 116	\$ 123	-5.7%	-5.7%	-	\$ 422	\$ 449	-6.0%	-6.0%	-
Intl	357	367	-2.7%	4.8%	-7.5%	1,436	1,467	-2.1%	0.8%	-2.9%
WW	473	490	-3.5%	2.1%	-5.6%	1,858	1,916	-3.0%	-0.8%	-2.2%
<b>BEAUTY</b>										
US	612	596	2.7%	2.7%	-	2,403	2,335	2.9%	2.9%	-
Intl	499	514	-2.9%	2.4%	-5.3%	1,979	1,865	6.1%	6.2%	-0.1%
WW	1,111	1,110	0.1%	2.5%	-2.4%	4,382	4,200	4.3%	4.4%	-0.1%
<b>ORAL CARE</b>										
US	165	156	5.8%	5.8%	-	637	616	3.4%	3.4%	-
Intl	234	237	-1.3%	3.5%	-4.8%	918	915	0.3%	0.5%	-0.2%
WW	399	393	1.5%	4.4%	-2.9%	1,555	1,531	1.6%	1.7%	-0.1%
<b>OTC</b>										
US	491	406	20.9%	20.9%	-	1,850	1,716	7.8%	7.8%	-
Intl	657	699	-6.0%	-2.0%	-4.0%	2,484	2,410	3.1%	2.1%	1.0%
WW	1,148	1,105	3.9%	6.4%	-2.5%	4,334	4,126	5.0%	4.4%	0.6%
<b>WOMEN'S HEALTH</b>										
US	3	3	0.0%	0.0%	-	13	12	8.3%	8.3%	-
Intl	254	259	-1.9%	7.9%	-9.8%	1,036	1,038	-0.2%	3.5%	-3.7%
WW	257	262	-1.9%	7.8%	-9.7%	1,049	1,050	-0.1%	3.5%	-3.6%
<b>WOUND CARE / OTHER</b>										
US	92	95	-3.2%	-3.2%	-	436	437	-0.2%	-0.2%	-
Intl	56	85	-34.1%	-31.2%	-2.9%	239	342	-30.1%	-30.2%	0.1%
WW	148	180	-17.8%	-16.4%	-1.4%	675	779	-13.4%	-13.5%	0.1%
<b>TOTAL CONSUMER</b>										
US	1,479	1,379	7.3%	7.3%	-	5,761	5,565	3.5%	3.5%	-
Intl	2,057	2,161	-4.8%	0.8%	-5.6%	8,092	8,037	0.7%	1.4%	-0.7%
WW	\$ 3,536	\$ 3,540	-0.1%	3.3%	-3.4%	\$ 13,853	\$ 13,602	1.8%	2.2%	-0.4%

REPORTED SALES vs. PRIOR PERIOD (\$MM)

**PHARMACEUTICAL SEGMENT <sup>(2)(5)</sup>**

	FOURTH QUARTER					TWELVE MONTHS				
	2018	2017	% Change			2018	2017	% Change		
			Reported	Operational <sup>(1)</sup>	Currency			Reported	Operational <sup>(1)</sup>	Currency
<b>IMMUNOLOGY</b>										
US	\$ 2,356	\$ 2,227	5.8%	5.8%	-	\$ 9,073	\$ 8,871	2.3%	2.3%	-
Intl	986	859	14.8%	19.8%	-5.0%	4,047	3,373	20.0%	18.9%	1.1%
WW	3,342	3,086	8.3%	9.7%	-1.4%	13,120	12,244	7.2%	6.9%	0.3%
<b>REMICADE</b>										
US	843	1,073	-21.4%	-21.4%	-	3,664	4,525	-19.0%	-19.0%	-
US Exports <sup>(3)</sup>	90	115	-21.7%	-21.7%	-	436	563	-22.6%	-22.6%	-
Intl	305	278	9.7%	15.4%	-5.7%	1,226	1,227	-0.1%	0.5%	-0.6%
WW	1,238	1,466	-15.6%	-14.5%	-1.1%	5,326	6,315	-15.7%	-15.6%	-0.1%
<b>SIMPONI / SIMPONI ARIA</b>										
US	272	253	7.5%	7.5%	-	1,051	954	10.2%	10.2%	-
Intl	210	237	-11.4%	-6.3%	-5.1%	1,033	879	17.5%	16.7%	0.8%
WW	482	490	-1.6%	0.9%	-2.5%	2,084	1,833	13.7%	13.3%	0.4%
<b>STELARA</b>										
US	1,009	740	36.4%	36.4%	-	3,469	2,767	25.4%	25.4%	-
Intl	435	341	27.6%	32.0%	-4.4%	1,687	1,244	35.6%	32.7%	2.9%
WW	1,444	1,081	33.6%	35.0%	-1.4%	5,156	4,011	28.5%	27.6%	0.9%
<b>TREMFYA</b>										
US	142	46	*	*	-	453	62	*	*	-
Intl	33	1	*	*	*	91	1	*	*	*
WW	175	47	*	*	*	544	63	*	*	*
<b>OTHER IMMUNOLOGY<sup>(5)</sup></b>										
US	-	-	-	-	-	-	-	-	-	-
Intl	3	2	50.0%	53.1%	-3.1%	10	22	-54.5%	-54.0%	-0.5%
WW	3	2	50.0%	53.1%	-3.1%	10	22	-54.5%	-54.0%	-0.5%
<b>INFECTIOUS DISEASES</b>										
US	372	338	10.1%	10.1%	-	1,378	1,358	1.5%	1.5%	-
Intl	430	462	-6.9%	-2.4%	-4.5%	1,926	1,796	7.2%	5.4%	1.8%
WW	802	800	0.3%	2.9%	-2.6%	3,304	3,154	4.8%	3.8%	1.0%
<b>EDURANT / rilpivirine</b>										
US	16	14	14.3%	14.3%	-	58	58	0.0%	0.0%	-
Intl	177	178	-0.6%	3.0%	-3.6%	758	656	15.5%	11.1%	4.4%
WW	193	192	0.5%	3.9%	-3.4%	816	714	14.3%	10.3%	4.0%
<b>PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA</b>										
US	322	285	13.0%	13.0%	-	1,169	1,109	5.4%	5.4%	-
Intl	173	185	-6.5%	-2.3%	-4.2%	786	712	10.4%	9.5%	0.9%
WW	495	470	5.3%	7.0%	-1.7%	1,955	1,821	7.4%	7.0%	0.4%
<b>OTHER INFECTIOUS DISEASES</b>										
US	34	39	-12.8%	-12.8%	-	151	191	-20.9%	-20.9%	-
Intl	80	99	-19.2%	-12.7%	-6.5%	382	428	-10.7%	-10.1%	-0.6%
WW	114	138	-17.4%	-12.8%	-4.6%	533	619	-13.9%	-13.5%	-0.4%

See footnotes at end of schedule

REPORTED SALES vs. PRIOR PERIOD (\$MM)

	FOURTH QUARTER					TWELVE MONTHS					
	2018	2017	% Change			2018	2017	% Change			
			Reported	Operational <sup>(1)</sup>	Currency			Reported	Operational <sup>(1)</sup>	Currency	
<b>NEUROSCIENCE</b>											
US	660	699	-5.6%	-5.6%	-	2,574	2,630	-2.1%	-2.1%	-	
Intl	840	825	1.8%	6.3%	-4.5%	3,503	3,356	4.4%	3.3%	1.1%	
WW	1,500	1,524	-1.6%	0.8%	-2.4%	6,077	5,986	1.5%	0.9%	0.6%	
<u>CONCERTA / methylphenidate</u>											
US	38	100	-62.0%	-62.0%	-	229	384	-40.4%	-40.4%	-	
Intl	112	103	8.7%	13.2%	-4.5%	434	407	6.6%	6.7%	-0.1%	
WW	150	203	-26.1%	-23.8%	-2.3%	663	791	-16.2%	-16.2%	0.0%	
<u>INVEGA SUSTENNA / XEPLION / TRINZA / TREVICTA</u>											
US	485	436	11.2%	11.2%	-	1,791	1,590	12.6%	12.6%	-	
Intl	278	257	8.2%	12.6%	-4.4%	1,137	979	16.1%	13.7%	2.4%	
WW	763	693	10.1%	11.7%	-1.6%	2,928	2,569	14.0%	13.1%	0.9%	
<u>RISPERDAL CONSTA</u>											
US	77	87	-11.5%	-11.5%	-	315	360	-12.5%	-12.5%	-	
Intl	101	110	-8.2%	-3.6%	-4.6%	422	445	-5.2%	-6.4%	1.2%	
WW	178	197	-9.6%	-7.1%	-2.5%	737	805	-8.4%	-9.1%	0.7%	
<u>OTHER NEUROSCIENCE</u>											
US	60	76	-21.1%	-21.1%	-	239	296	-19.3%	-19.3%	-	
Intl	349	355	-1.7%	2.8%	-4.5%	1,510	1,525	-1.0%	-1.6%	0.6%	
WW	409	431	-5.1%	-1.4%	-3.7%	1,749	1,821	-4.0%	-4.5%	0.5%	
<b>ONCOLOGY</b>											
US	1,063	891	19.3%	19.3%	-	4,331	3,098	39.8%	39.8%	-	
Intl	1,426	1,148	24.2%	29.2%	-5.0%	5,513	4,160	32.5%	30.4%	2.1%	
WW	2,489	2,039	22.1%	24.9%	-2.8%	9,844	7,258	35.6%	34.4%	1.2%	
<u>DARZALEX</u>											
US	323	241	34.0%	34.0%	-	1,203	884	36.1%	36.1%	-	
Intl	261	130	*	*	*	822	358	*	*	*	
WW	584	371	57.4%	59.6%	-2.2%	2,025	1,242	63.0%	62.4%	0.6%	
<u>IMBRUVICA</u>											
US	318	219	45.2%	45.2%	-	1,129	841	34.2%	34.2%	-	
Intl	385	303	27.1%	34.1%	-7.0%	1,486	1,052	41.3%	39.9%	1.4%	
WW	703	522	34.7%	38.8%	-4.1%	2,615	1,893	38.1%	37.3%	0.8%	
<u>VELCADE</u>											
US	-	-	-	-	-	-	-	-	-	-	
Intl	252	271	-7.0%	-3.1%	-3.9%	1,116	1,114	0.2%	-2.0%	2.2%	
WW	252	271	-7.0%	-3.1%	-3.9%	1,116	1,114	0.2%	-2.0%	2.2%	
<u>ZYTIGA</u>											
US	351	402	-12.7%	-12.7%	-	1,771	1,228	44.2%	44.2%	-	
Intl	435	353	23.2%	27.1%	-3.9%	1,727	1,277	35.2%	32.2%	3.0%	
WW	786	755	4.1%	5.9%	-1.8%	3,498	2,505	39.6%	38.1%	1.5%	
<u>OTHER ONCOLOGY</u>											
US	71	29	*	*	-	228	145	57.2%	57.2%	-	
Intl	93	91	2.2%	7.0%	-4.8%	362	359	0.8%	-0.2%	1.0%	
WW	164	120	36.7%	40.3%	-3.6%	590	504	17.1%	16.4%	0.7%	
<b>PULMONARY HYPERTENSION<sup>(4)</sup></b>											
US	436	365	19.5%	19.5%	-	1,651	773	*	*	-	
Intl	231	245	-5.7%	-1.7%	-4.0%	922	554	66.4%	64.2%	2.2%	
WW	667	610	9.3%	10.9%	-1.6%	2,573	1,327	93.9%	93.0%	0.9%	
<u>OPSUMIT</u>											
US	189	146	29.5%	29.5%	-	700	320	*	*	-	
Intl	134	123	8.9%	13.8%	-4.9%	515	253	*	*	*	
WW	323	269	20.1%	22.3%	-2.2%	1,215	573	*	*	*	
<u>TRACLEER</u>											
US	60	76	-21.1%	-21.1%	-	268	161	66.5%	66.5%	-	
Intl	64	91	-29.7%	-27.2%	-2.5%	278	242	14.9%	13.2%	1.7%	
WW	124	167	-25.7%	-24.4%	-1.3%	546	403	35.5%	34.5%	1.0%	
<u>UPTRAVI</u>											
US	165	117	41.0%	41.0%	-	598	238	*	*	-	
Intl	16	13	23.1%	27.3%	-4.2%	65	25	*	*	*	
WW	181	130	39.2%	39.6%	-0.4%	663	263	*	*	*	
<u>OTHER</u>											
US	22	26	-15.4%	-15.4%	-	85	54	57.4%	57.4%	-	
Intl	17	18	-5.6%	0.7%	-6.3%	64	34	88.2%	89.1%	-0.9%	
WW	39	44	-11.4%	-8.9%	-2.5%	149	88	69.3%	69.6%	-0.3%	
<b>CARDIOVASCULAR / METABOLISM / OTHER</b>											
US	1,049	1,256	-16.5%	-16.5%	-	4,279	4,744	-9.8%	-9.8%	-	
Intl	341	366	-6.8%	-1.5%	-5.3%	1,537	1,543	-0.4%	-1.2%	0.8%	
WW	1,390	1,622	-14.3%	-13.1%	-1.2%	5,816	6,287	-7.5%	-7.7%	0.2%	
<u>XARELTO</u>											
US	608	710	-14.4%	-14.4%	-	2,477	2,500	-0.9%	-0.9%	-	
Intl	-	-	-	-	-	-	-	-	-	-	
WW	608	710	-14.4%	-14.4%	-	2,477	2,500	-0.9%	-0.9%	-	
<u>INVOKANA / INVOKAMET</u>											
US	188	221	-14.9%	-14.9%	-	711	944	-24.7%	-24.7%	-	
Intl	40	46	-13.0%	-7.9%	-5.1%	170	167	1.8%	1.3%	0.5%	
WW	228	267	-14.6%	-13.7%	-0.9%	881	1,111	-20.7%	-20.8%	0.1%	
<u>PROCIT / EPREX</u>											
US	151	164	-7.9%	-7.9%	-	674	675	-0.1%	-0.1%	-	
Intl	70	68	2.9%	6.7%	-3.8%	314	297	5.7%	3.7%	2.0%	
WW	221	232	-4.7%	-3.6%	-1.1%	988	972	1.6%	1.0%	0.6%	
<u>OTHER</u>											
US	102	161	-36.6%	-36.6%	-	417	625	-33.3%	-33.3%	-	
Intl	231	252	-8.3%	-2.5%	-5.8%	1,053	1,079	-2.4%	-3.0%	0.6%	
WW	333	413	-19.4%	-15.9%	-3.5%	1,470	1,704	-13.7%	-14.1%	0.4%	
<b>TOTAL PHARMACEUTICAL</b>											
US	5,936	5,776	2.8%	2.8%	-	23,286	21,474	8.4%	8.4%	-	
Intl	4,254	3,905	8.9%	13.7%	-4.8%	17,448	14,782	18.0%	16.5%	1.5%	
WW	\$ 10,190	\$ 9,681	5.3%	7.2%	-1.9%	\$ 40,734	\$ 36,256	12.4%	11.8%	0.6%	

See footnotes at end of schedule

REPORTED SALES vs. PRIOR PERIOD (\$MM)

	FOURTH QUARTER					TWELVE MONTHS				
	2018	2017	Reported	% Change Operational <sup>(1)</sup>	Currency	2018	2017	Reported	% Change Operational <sup>(1)</sup>	Currency
<b>MEDICAL DEVICES SEGMENT <sup>(2)(5)</sup></b>										
<b>DIABETES CARE <sup>(6)</sup></b>										
US	\$ -	\$ 130	*	*	-	\$ 371	\$ 612	-39.4%	-39.4%	-
Intl	-	260	*	*	*	638	1,003	-36.4%	-36.8%	0.4%
WW	-	390	*	*	*	1,009	1,615	-37.5%	-37.7%	0.2%
<b>DIAGNOSTICS</b>										
US	-	-	-	-	-	-	-	-	-	-
Intl	-	-	-	-	-	-	1	*	*	*
WW	-	-	-	-	-	-	1	*	*	*
<b>INTERVENTIONAL SOLUTIONS</b>										
US	336	305	10.2%	10.2%	0.0%	1,283	1,148	11.8%	11.8%	-
Intl	350	316	10.8%	14.2%	-3.4%	1,363	1,148	18.7%	16.5%	2.2%
WW	686	621	10.5%	12.2%	-1.7%	2,646	2,296	15.2%	14.1%	1.1%
<b>ORTHOPAEDICS</b>										
US	1,358	1,370	-0.9%	-0.9%	-	5,281	5,404	-2.3%	-2.3%	-
Intl	904	916	-1.3%	2.4%	-3.7%	3,604	3,654	-1.4%	-2.9%	1.5%
WW	2,262	2,286	-1.0%	0.5%	-1.5%	8,885	9,058	-1.9%	-2.5%	0.6%
<b>HIPS</b>										
US	220	215	2.3%	2.3%	-	841	827	1.7%	1.7%	-
Intl	145	149	-2.7%	1.4%	-4.1%	577	567	1.8%	0.5%	1.3%
WW	365	364	0.3%	2.0%	-1.7%	1,418	1,394	1.7%	1.2%	0.5%
<b>KNEES</b>										
US	239	246	-2.8%	-2.8%	-	911	948	-3.9%	-3.9%	-
Intl	153	151	1.3%	5.2%	-3.9%	591	575	2.8%	1.5%	1.3%
WW	392	397	-1.3%	0.2%	-1.5%	1,502	1,523	-1.4%	-1.9%	0.5%
<b>TRAUMA</b>										
US	403	397	1.5%	1.5%	-	1,599	1,576	1.5%	1.5%	-
Intl	271	272	-0.4%	3.4%	-3.8%	1,100	1,040	5.8%	4.2%	1.6%
WW	674	669	0.7%	2.2%	-1.5%	2,699	2,616	3.2%	2.5%	0.7%
<b>SPINE &amp; OTHER</b>										
US	496	512	-3.1%	-3.1%	-	1,930	2,053	-6.0%	-6.0%	-
Intl	335	344	-2.6%	0.9%	-3.5%	1,336	1,472	-9.2%	-10.7%	1.5%
WW	831	856	-2.9%	-1.5%	-1.4%	3,266	3,525	-7.3%	-7.9%	0.6%
<b>SURGERY</b>										
US	1,094	1,076	1.7%	1.7%	-	4,125	4,085	1.0%	1.0%	-
Intl	1,493	1,482	0.7%	5.4%	-4.7%	5,776	5,474	5.5%	5.1%	0.4%
WW	2,587	2,558	1.1%	3.8%	-2.7%	9,901	9,559	3.6%	3.4%	0.2%
<b>ADVANCED</b>										
US	441	430	2.6%	2.6%	-	1,657	1,620	2.3%	2.3%	-
Intl	614	593	3.5%	8.0%	-4.5%	2,345	2,136	9.8%	9.1%	0.7%
WW	1,055	1,023	3.1%	5.7%	-2.6%	4,002	3,756	6.5%	6.1%	0.4%
<b>GENERAL</b>										
US	469	452	3.8%	3.8%	-	1,751	1,728	1.3%	1.3%	-
Intl	712	718	-0.8%	3.9%	-4.7%	2,806	2,735	2.6%	2.2%	0.4%
WW	1,181	1,170	0.9%	3.8%	-2.9%	4,557	4,463	2.1%	1.8%	0.3%
<b>SPECIALTY</b>										
US	184	194	-5.2%	-5.2%	-	717	737	-2.7%	-2.7%	-
Intl	167	171	-2.3%	2.7%	-5.0%	625	603	3.6%	4.2%	-0.6%
WW	351	365	-3.8%	-1.4%	-2.4%	1,342	1,340	0.1%	0.4%	-0.3%
<b>VISION</b>										
US	426	433	-1.6%	-1.6%	-	1,777	1,575	12.8%	12.8%	-
Intl	707	686	3.1%	6.8%	-3.7%	2,776	2,488	11.6%	11.0%	0.6%
WW	1,133	1,119	1.3%	3.6%	-2.3%	4,553	4,063	12.1%	11.8%	0.3%
<b>CONTACT LENSES / OTHER</b>										
US	289	290	-0.3%	-0.3%	-	1,237	1,122	10.2%	10.2%	-
Intl	527	510	3.3%	7.2%	-3.9%	2,065	1,914	7.9%	7.4%	0.5%
WW	816	800	2.0%	4.5%	-2.5%	3,302	3,036	8.8%	8.5%	0.3%
<b>SURGICAL</b>										
US	137	143	-4.2%	-4.2%	-	540	453	19.2%	19.2%	-
Intl	180	176	2.3%	5.3%	-3.0%	711	574	23.9%	23.1%	0.8%
WW	317	319	-0.6%	1.1%	-1.7%	1,251	1,027	21.8%	21.4%	0.4%
<b>TOTAL MEDICAL DEVICES</b>										
US	3,214	3,314	-3.0%	-3.0%	-	12,837	12,824	0.1%	0.1%	-
Intl	3,454	3,660	-5.6%	-1.4%	-4.2%	14,157	13,768	2.8%	1.9%	0.9%
WW	\$ 6,668	\$ 6,974	-4.4%	-2.2%	-2.2%	\$ 26,994	\$ 26,592	1.5%	1.1%	0.4%

\* Percentage greater than 100% or not meaningful

(1) Operational growth excludes the effect of translational currency

(2) Unaudited

(3) Reported as U.S. sales

(4) Products acquired from Actelion acquisition on June 16, 2017

(5) Prior year amounts have been reclassified to conform to current year product disclosure

(6) Reflects LifeScan divestiture October 2, 2018

**Pharmaceutical Supplemental Schedule**

Prior quarter amounts have been reclassified to conform to current quarter product disclosure (\$MM)

**PHARMACEUTICAL SEGMENT<sup>(1)</sup>**

TREMFYA

US	62
Intl	1
WW	<u>63</u>

OTHER IMMUNOLOGY<sup>(2)</sup>

US	-
Intl	22
WW	<u>22</u>

2017	2018			
	Q1	Q2	Q3	Q4
Full Year				
	66	102	143	142
	<u>6</u>	<u>24</u>	<u>28</u>	<u>33</u>
	72	126	171	175
	-	-	-	-
	<u>2</u>	<u>3</u>	<u>2</u>	<u>3</u>
	2	3	2	3

(1) Unaudited

(2) Prior year amounts have been reclassified to conform to current year product disclosure